Skip to main content
logo
Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.030
-0.100 (-2.42%)
Nov 2, 2026, 3:02 PM EST - Market open

Taysha Gene Therapies Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
5.499.778.3315.452.5-
Revenue Growth
-32.27%17.28%-46.07%517.55%--
Gross Profit
5.499.778.3315.452.5-
Operating Income
-153.16-110.5-86.62-71.37-126.03-173.27
Net Income
-149.63-109-89.3-111.57-166.01-174.52
Earnings Per Share
-0.41-0.34-0.36-0.96-3.78-4.64
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
455.41319.77139.04143.9487.88149.1
Total Debt
56.7170.1463.1861.1159.9363.09
Net Cash (Debt)
398.69249.6275.8682.8327.9586.01
Net Cash Growth
57.59%229.08%-8.42%196.34%-67.50%-65.77%
Net Cash Per Share
1.100.780.300.710.642.28

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-132.19-93.09-81.23-73.02-88.39-117.04
Capital Expenditures
-0.38-0.74-0.37-3.87-20.62-15.3
Free Cash Flow
-132.57-93.83-81.6-76.89-109.01-132.35
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%-
Operating Margin
-2792.32%-1130.65%-1039.49%-461.94%-5037.05%-
Pretax Margin
-2728.04%-1115.27%-1071.62%-722.06%-6635.25%-
Profit Margin
-2728.04%-1115.27%-1071.62%-722.06%-6635.25%-
FCF Margin
-2416.99%-960.07%-979.23%-497.62%-4356.88%-

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
241.18154.1642.5521.4256.40-